The Outcome of Coronavirus Disease 2019 among People Living with HIV in European Union versus Non-European Union Countries
Makaleler > Tam Makale · 2025
Yazarlar: Agata Skrzat-Klapaczyńska, Botond Lakatos, Gordana Dragovic, Velida Mulabdic, Cristiana Oprea, Ayşe Deniz GÖKENGİN, Antonija Verhaz, Ivailo Alexiev, Lidia Placinta, Ivana Gmizic, Nino Rukhadze, Nicolina Bogdanic, Natalie Bolokadze, Tiberiu Holban, Justyna Dominika Kowalska
Archives of Medical Science, Uluslararası, Wos, 2025
DOI: 10.5114/aoms/208856
Özet
Introduction The Central and Eastern Europe (CEE) region differs in access to HIV and co-infections care and treatment. The aim of the study was to analyze the relation between the severity of the COVID-19 disease and HIV specific factors in the European Union (EU) Countries and in non-European Union (non-EU) Countries. Material and methods The study was conducted between November 2020 and May 2021. Euroguidelines in Central and Eastern Europe (ECEE) Network Group was collecting observational data on HIV-positive patients diagnosed with COVID-19. In total, 16 countries from CEE (Poland, Czech Republic, Ukraine, Croatia, Turkey, Romania, Belarus, Estonia, Lithuania, Greece, Georgia, Albania, Hungary, Serbia, Bosnia and Herzegovina, and Bulgaria) submitted data on HIV-positive patients using an electronic case report form (eCRF). Chi-Square test was used for group comparisons. Results In total 557 patients were included into the analyses: 361 from EU and 196 from non-EU countries. Access to remdesivir was 1.5% in non-EU countries vs 3.9% in EU-countries (p= 0.1952) . Symptoms of COVID-19 occurred more often in non-EU countries (93.3%) vs non-EU countries (83.6%) [p=0.0009], as well as hospitalization 32.8% vs. 20.8% respectively [0.0027]. Death/ICU was 4.8% in non-EU countries vs 3.4% in EU-countries (p=0.4877). In total 18 (3.23%) patients found out about HIV diagnosis during COVID-19, which was comparable in two groups (11 [3.0%] in UE countries vs. 7 [3.6%] in non-UE countries; p=0.8029). Conclusions Patients from non- EU countries were more likely to be COVID-19 symptomatic and hospitalized. Access to antiviral therapy for SARS-CoV-2 was very low for all CEE countries.